RxDoctor Payments Data

Walter Thomas

Medical · Culver City, CANPI 1154516789

Payments from drug & device makers

$4,938in general payments, 2019–2025

Across 234 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$719
  • Novo Nordisk$546
  • GSK$444
  • Lilly USA, LLC$390
  • AstraZeneca$386
  • Esperion Therapeutics, Inc.$312
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,938 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.

See all medical providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$107,249
FarxigaDapagliflozin Propanediol110$104,955
OzempicSemaglutide109$103,578
JanuviaSitagliptin Phosphate84$83,393
JanumetSitagliptin Phos/Metformin Hcl38$41,138
ProliaDenosumab15$25,088
TradjentaLinagliptin28$20,308
EliquisApixaban23$19,096
XareltoRivaroxaban17$14,331
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$9,548
Tresiba Flextouch U-100Insulin Degludec16$9,359
Atorvastatin Calcium882$8,951
KerendiaFinerenone12$8,774
Tresiba Flextouch U-200Insulin Degludec14$8,392
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$7,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$266$127,557131 claims
MerckJanuvia, Janumet$125$124,531122 claims
AstraZenecaFarxiga$386$104,955110 claims
Novo NordiskOzempic$546$103,578109 claims
AmgenProlia$719$25,08815 claims
Johnson & JohnsonXarelto, Invokana$243$21,08629 claims
PfizerEliquis$196$19,09623 claims
BayerKerendia$218$8,77412 claims
Sanofi-aventis U.S. LLCLantus$109$1,87123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.

Other medical in Culver City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →